Ayala Pharmaceuticals, Inc.
ADXS evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $25.7M
- Lead Asset:
- ADXS-PSA (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ADXS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 1 pipeline candidate for Ayala Pharmaceuticals, Inc..
Run Ayala Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ayala Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is Ayala Pharmaceuticals, Inc.'s lead drug candidate?
Ayala Pharmaceuticals, Inc.'s most advanced tracked candidate is ADXS-PSA (Phase 2) for Metastatic castration-resistant prostate cancer (mCRPC), previously treated patients.
Who is the CEO of Ayala Pharmaceuticals, Inc.?
Mr. Kenneth A. Berlin J.D. is the chief executive officer of Ayala Pharmaceuticals, Inc. (ADXS).
Where is Ayala Pharmaceuticals, Inc. headquartered?
Ayala Pharmaceuticals, Inc. (ADXS) is headquartered in Monmouth Junction, NJ, United States.
What therapeutic areas does Ayala Pharmaceuticals, Inc. focus on?
Ayala Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.